25
Jun 2026
A study published in Current Molecular Pharmacology provides a comprehensive analysis of microRNA-29a (miR-29a) as a pivotal regulator in cancer development, and examines how natural bioactive compounds may offer a promising strategy for cancer prevention by modulating its expression.
25
Jun 2026
As we age, the immune system gradually declines and becomes less effective at responding to infections and vaccines.
25
Jun 2026
A study published recently in Current Molecular Pharmacology has uncovered a key mechanism linking aging to persistent pulmonary fibrosis, identifying the transcriptional regulator fPRDM16 as a potential therapeutic target.
25
Jun 2026
A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.
25
Jun 2026
Taking a supplement before a hepatectomy, a surgery in which part of the liver is removed, may help the organ recover more quickly and become more resistant to further damage.
25
Jun 2026
Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that firmly centers scientists' expertise to find viable target antigens for CAR T cell therapy.
25
Jun 2026
Chronic psychological stress can help tumors evade immune attack through a chain of molecular events involving gut bacteria and viruses within those bacteria, according to a study led by Weill Cornell Medicine investigators.
25
Jun 2026
Markers of a new mechanism for cell death, called karyoptosis, have been found in brains of patients with Alzheimer's disease and frontotemporal dementia (FTD).
25
Jun 2026
Our cells rely on tightly regulated signaling pathways to control when they grow, divide, and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably and become cancerous.
25
Jun 2026
Aston University has been awarded €1.2m through the Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges program for a project bringing together 18 partner organizations to develop unique cancer-fighting 'magnetobots'.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
